

Press Release
18 March 2021 08:00:00 CET



Newbury Closes Series A Funding Round

Swedish-based Newbury Pharmaceuticals AB, a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands, has successfully completed its Series A funding round of 25 MSEK.

The oversubscribed Series A financing brings 25 MSEK from selected strategic investors. Proceeds from the funding round will support to continue building a pipeline of proprietary and licensed products. The portfolio strategy includes niche and value-added small molecules, product development based on peptide technology as well as biosimilars in a variety of therapeutic categories.

"We have the ambition to become the local champion and alternative partner to the multinationals. We strive to have a positive impact in the society, bring products and technology that contribute to the overall healthcare system and patient's wellbeing – and give our partner the local attention they deserve" says Karl Karlsson, Founder & CEO.

For more information contact:

Karl Karlsson, Founder, Executive Chairman

karl.karlsson@newburypharma.com

Mobil: +46-46-121 120

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury Pharmaceuticals wants to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging its experience and extensive international network whereby Newbury can offer strategic partnerships of innovation for the benefit of the Nordic healthcare market.